Weekly Investment Analysts’ Ratings Updates for Boston Scientific (BSX)

Posted by Linda Flegge on Feb 10th, 2026

Boston Scientific logo Several brokerages have updated their recommendations and price targets on shares of Boston Scientific (NYSE: BSX) in the last few weeks:

2/7/2026 – Boston Scientific was downgraded by analysts at Wall Street Zen from a “buy” rating to a “hold” rating.
2/6/2026 – Boston Scientific had its “outperform” rating reaffirmed by analysts at Sanford C. Bernstein. They now have a $112.00 price target on the stock.
2/5/2026 – Boston Scientific was given a new $99.00 price target on by analysts at The Goldman Sachs Group, Inc..
2/5/2026 – Boston Scientific had its price target lowered by analysts at UBS Group AG from $140.00 to $120.00. They now have a “buy” rating on the stock.
2/5/2026 – Boston Scientific had its price target lowered by analysts at Citigroup Inc. from $130.00 to $102.00. They now have a “buy” rating on the stock.
2/5/2026 – Boston Scientific had its price target lowered by analysts at Canaccord Genuity Group Inc. from $131.00 to $112.00. They now have a “buy” rating on the stock.
2/5/2026 – Boston Scientific had its price target lowered by analysts at JPMorgan Chase & Co. from $135.00 to $100.00. They now have an “overweight” rating on the stock.
2/5/2026 – Boston Scientific had its price target lowered by analysts at Royal Bank Of Canada from $130.00 to $115.00. They now have an “outperform” rating on the stock.
2/5/2026 – Boston Scientific had its price target lowered by analysts at Evercore Inc from $112.00 to $96.00. They now have an “outperform” rating on the stock.
2/5/2026 – Boston Scientific had its price target lowered by analysts at Wells Fargo & Company from $125.00 to $94.00. They now have an “overweight” rating on the stock.
2/5/2026 – Boston Scientific had its price target lowered by analysts at Morgan Stanley from $130.00 to $118.00. They now have an “overweight” rating on the stock.
2/5/2026 – Boston Scientific had its price target lowered by analysts at Needham & Company LLC from $121.00 to $97.00. They now have a “buy” rating on the stock.
2/5/2026 – Boston Scientific had its price target lowered by analysts at Truist Financial Corporation from $120.00 to $95.00. They now have a “buy” rating on the stock.
2/5/2026 – Boston Scientific had its price target lowered by analysts at Mizuho from $140.00 to $115.00. They now have an “outperform” rating on the stock.
2/5/2026 – Boston Scientific had its price target lowered by analysts at Robert W. Baird from $118.00 to $101.00. They now have an “outperform” rating on the stock.
2/4/2026 – Boston Scientific had its price target lowered by analysts at Stifel Nicolaus from $125.00 to $110.00. They now have a “buy” rating on the stock.
2/4/2026 – Boston Scientific had its “buy” rating reaffirmed by analysts at BTIG Research.
2/4/2026 – Boston Scientific had its price target lowered by analysts at BTIG Research from $132.00 to $110.00. They now have a “buy” rating on the stock.
2/4/2026 – Boston Scientific was downgraded by analysts at Weiss Ratings from a “buy (b-)” rating to a “hold (c+)” rating.
2/3/2026 – Boston Scientific had its price target lowered by analysts at Barclays PLC from $136.00 to $124.00. They now have an “overweight” rating on the stock.
2/2/2026 – Boston Scientific was given a new $115.00 price target on by analysts at National Bankshares, Inc..
2/2/2026 – Boston Scientific had its price target lowered by analysts at TD Cowen from $115.00 to $100.00. They now have a “buy” rating on the stock.
1/21/2026 – Boston Scientific had its “buy (b-)” rating reaffirmed by analysts at Weiss Ratings.
1/17/2026 – Boston Scientific was upgraded by analysts at Wall Street Zen from a “hold” rating to a “buy” rating.
1/16/2026 – Boston Scientific had its price target lowered by analysts at Oppenheimer Holdings, Inc. from $125.00 to $100.00. They now have an “outperform” rating on the stock.
1/15/2026 – Boston Scientific had its “buy” rating reaffirmed by analysts at Needham & Company LLC.
1/14/2026 – Boston Scientific had its “buy” rating reaffirmed by analysts at Citigroup Inc..
1/9/2026 – Boston Scientific had its “buy” rating reaffirmed by analysts at The Goldman Sachs Group, Inc.. They now have a $112.00 price target on the stock.
1/5/2026 – Boston Scientific was given a new $112.00 price target on by analysts at Evercore Inc.
12/20/2025 – Boston Scientific was downgraded by analysts at Wall Street Zen from a “buy” rating to a “hold” rating.
12/18/2025 – Boston Scientific had its price target lowered by analysts at Truist Financial Corporation from $130.00 to $120.00. They now have a “buy” rating on the stock.
12/17/2025 – Boston Scientific had its “buy” rating reaffirmed by analysts at UBS Group AG.
12/17/2025 – Boston Scientific had its price target lowered by analysts at Canaccord Genuity Group Inc. from $132.00 to $131.00. They now have a “buy” rating on the stock.
12/17/2025 – Boston Scientific had its price target raised by analysts at Royal Bank Of Canada from $125.00 to $130.00. They now have an “outperform” rating on the stock.

Insider Activity at Boston Scientific

In related news, EVP Arthur C. Butcher sold 17,313 shares of the stock in a transaction that occurred on Monday, December 1st. The stock was sold at an average price of $101.55, for a total transaction of $1,758,135.15. Following the completion of the sale, the executive vice president directly owned 23,600 shares of the company’s stock, valued at approximately $2,396,580. This represents a 42.32% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Also, CEO Michael F. Mahoney sold 160,901 shares of Boston Scientific stock in a transaction that occurred on Monday, February 2nd. The shares were sold at an average price of $93.49, for a total transaction of $15,042,634.49. Following the completion of the transaction, the chief executive officer directly owned 1,411,735 shares in the company, valued at approximately $131,983,105.15. The trade was a 10.23% decrease in their position. The disclosure for this sale is available in the SEC filing. 0.50% of the stock is currently owned by insiders.

Boston Scientific Corporation (NYSE: BSX) is a global medical device company that develops, manufactures and markets a broad portfolio of products used in less-invasive medical procedures. Founded in 1979 by John Abele and Peter Nicholas, the company is headquartered in Marlborough, Massachusetts, and focuses on technologies that enable physicians to treat a wide range of cardiovascular, digestive, urologic, pulmonary and chronic pain conditions without open surgery.

Boston Scientific’s activities span product development, clinical research, regulatory affairs and commercial sales.